Back to Agenda
PMDA Townhall
Session Chair(s)
Daisuke Tanaka, PHD
Office Director, Office of International Programs, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
- Introduction of the PMDA’s plan and the direction to achieve, with the essence of its new 5-year mid-term plan scheduled from FY2024 - Clearing up misconceptions that have become bad urban legends about Japan when companies are considering R&D on new medicines in Japan - The attractiveness of performing R&D in Japan will be presented and clarified through discussions from the regulatory and industrial perspectives.
Learning Objective : 1. To recognize latest information on the Pharmaceuticals and Medical Devices Agency’s activity and Japanese regulations in medical products area. 2. To discuss issues on medical products regulation with senior PMDA officials
Speaker(s)
Shinobu Uzu, PHD
Senior Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Future Vision of PMDA - 5th Mid-Term Plan
Kenichi Tamiya, MSC, RPH
Associate Executive Director, Office of New Drug, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Major Initiatives for Promoting Drug Development in Japan
Atsushi Tsukamoto, PHD, MSC
Head is Therapeutic Area Strategies , Daiichi Sankyo, United States
Industry Perspective for Drug Development in Japan
Yves Jacob
Head of Global Regulatory Affairs Europe and R&D Lead, Sanofi-Aventis Recherche & Developpment, France
Panelist
Have an account?